A recent editorial paper was published in Oncoscience (Volume 10) on March 23, 2023, entitled, “Recent approach to clustering colorectal cancer patients using differential presence of exons (DPE) sequencing.”

Colorectal cancer (CRC) is a heterogeneous disease that happens within the colon and the rectum, parts of the gastrointestinal system. CRC is the third leading explanation for cancer-related death worldwide. The incidence and mortality of CRC is predicted to extend significantly in the longer term, with greater than 2.2 million recent cases and 1.1 million deaths expected by 2030.

Metastasis is the leading explanation for death in CRC patients, especially liver metastasis. In keeping with previous studies, about 25% of CRC cases are clinically diagnosed with liver metastases in early stages, and about 50% of CRC patients experience symptoms of liver metastases throughout the course of the disease. Differential presence of exons (DPE) by next generation sequencing (NGS) is an revolutionary method to research the entire exome sequence and could be used as a stratification and predictive tool in patients with colorectal cancer (CRC).

On this editorial, researchers David Rubio-Mangas, Mariano García-Arranz, Javier Suela and Damian GarcíaOlmo from Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid and Hospital Fundación Jiménez Díaz discuss DPE evaluation as an emerging and promising technique in the sphere of liquid biopsy that has the advantage of being non-invasive in comparison with invasive diagnostic techniques. As well as, this evaluation can provide priceless information on CRC progression and will provide information on response to therapy.

“The usage of liquid biopsy in clinical practice might also reduce the prices and time required for staging CRC patients, which could have implications for diagnosis and treatment.”

Source:

Impact Journals LLC- Oncoscience

Journal reference:

Rubio-Mangas, D., et al. (2023). Recent approach to clustering colorectal cancer patients using differential presence of exons (DPE) sequencing. Oncoscience. doi.org/10.18632/oncoscience.573.